(Q47738688)

English

Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration

scientific article published on 7 April 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

1 reference

based on heuristic

inferred from title

Katia Sparnacci

7

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

8

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

Riccardo Gavioli

10

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

11

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

object named as

Luisa Tondelli

9

0 references

Antonella Caputo

object named as

Antonella Caputo

1

0 references

Egidio Brocca-Cofano

3

object named as

Egidio Brocca-Cofano

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

Arianna Castaldello

2

object named as

Arianna Castaldello

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

4

object named as

Rebecca Voltan

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

author name string

Francesca Bortolazzi

5

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

Giuseppe Altavilla

6

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

language of work or name

0 references

publication date

7 April 2009

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

27

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

27

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

3605-3615

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Advances in vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Particulate delivery systems for vaccines: what can we expect?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

New advances in microsphere-based single-dose vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Starch microparticles as vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Effect of synthetic lipopeptides formulated in liposomes on the maturation of human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Polymer degradation and in vitro release of a model protein from poly(d,l-lactide-co-glycolide) nano- and microparticles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Formulation aspects of biodegradable polymeric microspheres for antigen delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Microparticles as vaccine adjuvants and delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Cationic microparticles: A potent delivery system for DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Cationic microparticles are a potent delivery system for a HCV DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Cationic microparticles consisting of poly(lactide-co-glycolide) and polyethylenimine as carriers systems for parental DNA vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Exploiting lymphatic transport and complement activation in nanoparticle vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

European union regulatory developments for new vaccine adjuvants and delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Core-shell microspheres by dispersion polymerization as promising delivery systems for proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Preparation and Characterization of Innovative Protein-coated Poly(Methylmethacrylate) Core-shell Nanoparticles for Vaccine Purposes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Candidate HIV-1 Tat vaccine development: from basic science to clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 ΔV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Recent advances in the development of HIV-1 Tat-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Problems and emerging approaches in HIV/AIDS vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

The therapeutic phase I trial of the recombinant native HIV-1 Tat protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Candidate HIV-1 gp140ΔV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

HIV-1 Tat-coated nanoparticles result in enhanced humoral immune responses and neutralizing antibodies compared to alum adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Functional polymeric nano/microparticles for surface adsorption and delivery of protein and DNA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.047

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.03.047

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 February 2018

http://europepmc.org/abstract/MED/19464541

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47738688&oldid=2169182968"